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Objectives The aim of this study was to ascertain the 1-year incidence of stent thrombosis (ST) and major bleeding (MB) in
a large, unselected population treated with sirolimus-eluting stents (SES).
Background Stent thrombosis and MB are major potential complications of drug-eluting stent implantation. Their relative
incidence and predisposing factors among large populations treated worldwide are unclear.
Methods The SES were implanted in 15,147 patients who were entered in a multinational registry. We analyzed the inci-
dence of: 1) definite and probable ST as defined by the Academic Research Consortium; and 2) MB, with the
STEEPLE (Safety and efficacy of Enoxaparin in PCI) definition, together with their relation to dual antiplatelet
therapy (DAPT) and to 1-year clinical outcomes.
Results The mean age of the sample was 62  11 years, 30.4% were diabetic, 10% had a Charlson comorbidity index
3, and 44% presented with acute coronary syndrome or myocardial infarction. At 1 year, the reported compli-
ance with DAPT as recommended by the European Society of Cardiology guidelines was 86.3%. Adverse event
rates were: ST 1.0%, MB 1.0%, mortality 1.7%, myocardial infarction 1.9%, and target lesion revascularization
2.3%. Multivariate analysis identified 9 correlates of ST and 4 correlates of MB. Advanced age and a high Charl-
son index were associated with an increased risk of both ST and MB. After ST, the 7-day and 1-year all-cause
mortality was 30% and 35%, respectively, versus 1.5% and 10% after MB. Only 2 of 13,749 patients (0.015%)
experienced both MB and ST during the entire 1-year follow-up period.
Conclusions In this worldwide population treated with 1 SES, the reported compliance with DAPT was good, and the inci-
dence of ST and MB was low. Stent thrombosis and MB very rarely occurred in the same patient. (The e-SELECT
Registry: a Multicenter Post-Market Surveillance; NCT00438919) (J Am Coll Cardiol 2011;57:1445–54)
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Thrombosis and Bleeding After SES Implant March 29, 2011:1445–54When compared with bare-metal
stents, drug-eluting stents (DES)
implanted during percutaneous
coronary intervention (PCI) have
markedly lowered the rate of re-
stenosis and the need for repeat
intervention (1). Stent thrombo-
sis (ST), albeit an infrequent
event, remains the main safety
concern and long-term compli-
cation associated with the use of
both bare-metal stents and DES.
Better implantation techniques
and stent designs (2,3), safer and
more effective antithrombotic
therapy (4,5), and a greater com-
pliance with antiplatelet regi-
mens (6) have all contributed to
lowering the rate of ST. The
reported rates of ST range from
0.7% to 1.7% in the first year and 0.2% to 0.6% in
subsequent years (1,7), depending on the definition used
(8), the type of DES implanted, and the population studied.
The current European Society of Cardiology (ESC) guide-
lines recommend uninterrupted dual antiplatelet therapy
(DAPT) for 6 to 12 months after DES implantation,
followed by long-term single antiplatelet therapy (9). How-
ever, antithrombotic therapy is associated with a risk of
bleeding, which is usually (4,10) though not always (11,12)
commensurate with its efficacy. In patients undergoing
treatment of acute coronary syndromes (ACS), bleeding is a
notorious complication associated with a markedly worse
prognosis and increased mortality (13–15).
Little information has been collected prospectively to
ascertain the incidence and consequences of bleeding in
unselected patients undergoing DES implantation for indi-
cations other than ACS (16,17), and the relationship
between long-term bleeding complications and ST in the
general population of DES recipients remains unclear. With
data from the e-SELECT (Multi-Center Post-Market
Surveillance) registry, a prospective observational registry of
patients who underwent implantation of sirolimus-eluting
stents (SES), we focused on the 1-year incidence and
consequences of ST and major bleeding (MB).
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Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
DAPT  dual antiplatelet
therapy
DES  drug-eluting stent(s)
ESC  European Society of
Cardiology
MACE  major adverse
cardiac event(s)
MB  major bleeding
MI  myocardial infarction
PCI  percutaneous
coronary intervention
SES  sirolimus-eluting
stent(s)
ST  stent thrombosisc
Manuscript received August 8, 2010; revised manuscript received October 13,
2010, accepted November 8, 2010.Methods
The e-SELECT registry was conducted at 320 medical centers
(listed in the Online Appendix) in 56 countries where SES
have been approved for commercial use. Baseline data were
collected between May 2006 and April 2008 in consecutive
and eligible patients who underwent implantation of 1
YPHER Select or CYPHER Select Plus (Cordis Corpora-
ion, Bridgewater, New Jersey) SES according to standard
linical practice and procedural techniques.
The protocol specified very few inclusion or exclusion
riteria. The investigators were encouraged to follow the
nstructions for use of SES, although implants for off-label
ndications were not prohibited. Lesions could be pre-
reated with any technique or device—such as balloon
ngioplasty, cutting balloon, or atherectomy—but implan-
ation of SES in each target lesion during the index
rocedure was mandatory. All post-operative medical man-
gement, including antithrombotic therapy, was prescribed
ccording to usual local practice. The protocol was approved
y the ethics committee of each participating medical
enter, and the patients granted their consent to participate
n the registry. Patients for whom the collection of depend-
ble follow-up information was unlikely and those who
eceived a stent other than a CYPHER SES during the
ndex procedure were excluded.
In September 2009, the patient follow-up was shortened
y the study sponsor from 3 years to 1 year, for logistic
easons and because of a concern that later results might be
ess relevant with changing patterns of stent use.
ata collection and management. The data collected by
he e-SELECT registry include demographic information,
ardiovascular history, comorbidity (18), lesion and proce-
ure characteristics, and antithrombotic regimens. The
atients were followed at 30, 180, and 360 days by tele-
hone communication or office visit by contacts with
rimary physicians or referring cardiologists.
The data were collected electronically at each participat-
ng medical center and transferred to an independent data
anagement organization (KIKA Medical, Nancy, France).
fter verification of their consistency, the data were ana-
yzed by an independent clinical research organization
Cardialysis, Rotterdam, the Netherlands). The accuracy of
ata collection was monitored by an independent organiza-
ion (Covance, Princeton, New Jersey) in 20% of the overall
ample, at 100 centers selected by a stratification scheme on
he basis of patient enrollment, region of the world, and rate
f data outliers. The consistency and accuracy of data
ontained in the source documentation versus that entered
n the electronic database was verified, with an anonymous
rocedure to preserve confidentiality. The data were con-
idered consistent when present in both the source docu-
ents and in the electronic database and accurate when the
lectronic database fully matched the data entered in the
ource documents. With these definitions, overall data
onsistency was 99%. The accuracy of baseline data was
1447JACC Vol. 57, No. 13, 2011 Urban et al.
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was 93.2%.
End points of the e-SELECT registry. The primary end
point of the registry was a composite of definite and
probable ST at 1 year of follow-up, as defined by the
Academic Research Consortium (8). The secondary end
points at 1 year included MB according to the STEEPLE
(Safety and efficacy of Enoxaparin in PCI) definition (19),
cardiac and noncardiac death, myocardial infarction (MI),
and major adverse cardiac events (MACE) (defined as any
death, MI, or target lesion revascularization [TLR]).
Study organization and supervision. A steering commit-
tee (Online Appendix) planned the analysis, presentations,
and publications of its results. The algorithms used to classify
clinical events and the criteria used for the adjudications of
MACE were developed by a Clinical Event Committee
(Online Appendix) composed of interventional cardiologists
who were not associated with the sponsor and were not
participants in the registry. The Committee adjudicated all
MACE, deaths, ST, and MB by a systematic review of the
data collection forms and by review of the source documents,
electrocardiograms, and angiograms, when necessary.
Statistical analysis. For all patients, standard descriptive
statistics were used for baseline, lesion, and procedural
characteristics and for clinical results. Continuous variables
are presented as mean  SD or median and range, and
categorical variables are presented as numbers and percent-
ages. Cumulative rates of adverse clinical events were
calculated with event-specific adjusted denominators, so
that all patients experiencing an event within 360 days or
followed up for at least 330 days after the index procedure
contributed to the denominator. There was no censoring.
Kaplan-Meier curves and time-to-event summaries were
constructed, with the life-table method, to examine the
long-term incidence of clinical and safety end points.
Predictors of major clinical safety end points were identified
by univariate and multivariate analyses with Cox propor-
tional hazards model. For each outcome end point, baseline
covariates identified by the univariate analysis (p  005), by
the proportional hazards assumption test (p  0.05 com-
bined with graphic assessment), and by clinical relevance
were included in the multivariate model stepwise selection
procedure—an entry criterion probability value of 0.10 and
a stay criterion of 0.15 were used, and baseline covariates
with 15% missing values were excluded from analysis. No
missing value imputation was performed. All statistical
analyses were performed with SAS (version 9.1 or higher
software, SAS Institute, Cary, North Carolina).
Results
Registry sample. The e-SELECT database registered
15,400 subjects, of whom 253 were de-registered after
online data queries and on-site monitoring of source data,
resulting in a sample of 15,147 patients compliant with the
inclusion/exclusion criteria specified in the protocol (seeMethods section). Patient baseline characteristics are listed
in Table 1. Follow-up data were available in 14,905 patients
at 30 days, 14,430 patients at 6 months, and 13,693 patients
at 1 year, representing 99%, 96%, and 92% of survivors at 30
days, 6 months, and 1 year, respectively.
Index procedure and lesions characteristics. A total of
23,492 SES were implanted during the index procedure, to
treat 19,988 lesions. The stent length ranged between 8 and
33 mm, and the nominal stent diameter ranged between
2.25 and 3.50 mm. Multiple SES were implanted in 38.5%
of patients. Important procedural characteristics are listed in
Baseline Characteristics of 15,147 PatientsIncluded in the e-SELECT RegistryTable 1 B seline Characteristics of 15,147 PatientsIncluded in the e-SELECT Registry
Age, yrs 62.1 10.8
Men 11,423 (75.4)
Body mass index 30 kg/m2 3,673 (24.4)
History of
Myocardial infarction 4,854 (32.2)
Percutaneous coronary intervention 4,850 (32.2)
Coronary artery bypass graft surgery 1,370 (9.1)
Diabetes 4,577 (30.4)
Insulin-nondependent 3,339 (22.1)
Insulin-dependent 1,238 (8.2)
Hypertension 10,171 (67.4)
Hyperlipidemia 10,289 (68.2)
Current smoking 3,030 (20.1)
Peripheral vascular disease 941 (6.2)
Cerebral vascular accident 643 (4.3)
Serum creatinine 177 mol/l 370 (2.5)
Malignancy 323 (2.1)
Chronic obstructive lung disease 597 (4.0)
Gastro-duodenal ulcer 423 (2.8)
Mean Charlson index score 1.1 1.3
Charlson index score 3 1,546 (10.3)
AVK treated before index procedure 296 (2.0)
Indications for index procedure
Stable angina 6,306 (41.6)
Unstable angina 3,922 (25.9)
Myocardial infarction
Acute (24 h) 1,234 (8.2)
Recent (24 h) 1,509 (10.0)
Silent ischemia/others 2,176 (14.4)
Number of diseased vessels
1 8,278 (54.7)
2 4,242 (28.0)
3 2,627 (17.3)
Location of target lesions
Left main coronary artery stenosis
Unprotected 254 (1.3)
Protected 169 (0.9)
Left anterior descending coronary artery 9,981 (51.0)
Circumflex coronary artery 4,291 (21.9)
Right coronary artery 5,076 (26.0)
Saphenous vein graft 317 (1.6)
Values are mean  SD or n (%) of observations. e-SELECT (Multi-Center Post-Market Surveillance)
registry.
AVK  antivitamin K agents; e-SELECT  Multi-Center Post-Market Surveillance.Table 2. At the time of discharge from the hospital, 98.7%
S
g
o
1448 Urban et al. JACC Vol. 57, No. 13, 2011
Thrombosis and Bleeding After SES Implant March 29, 2011:1445–54of patients were being treated with clopidogrel or ticlopidine
combined with aspirin. Table 3 shows the number of
patients treated with a thienopyridine, aspirin, or both, at 1,
6, and 12 months and the main indications for interrupting
or discontinuing the antithrombotic regimen. At the time of
discharge from the hospital, 98.6% of patients prescribed a
thienopyridine received clopidogrel, and 1.4% received
ticlopidine. No patient received prasugrel or ticagrelor,
which were not commercially available.
The DAPT was discontinued or interrupted during the
first 30 days in 2% of patients (Table 3). The incidence of
discontinuation increased after the first 6 months, mostly
upon the recommendations of physicians. When excluding
treatment interruptions lasting 5 days from the analysis,
86.3% of patients received 6 months of uninterrupted
DAPT, followed by uninterrupted single or dual antithrom-
botic therapy between 6 and 12 months, in compliance with
the ESC practice guidelines (9).
ST, MB, and other major adverse clinical events. The
30-, 180-, and 360-day rates of adverse clinical events are
presented in Table 4, and MB complications are illustrated
in Figure 1. By single variable analysis of 58 demographic,
clinical, angiographic, and procedural characteristics, 18, 10,
and 27 significant correlates of ST, MB, and death, respec-
tively, were identified. In addition, 3, 4, and 1 clinically
relevant correlates of ST, MB, and death, respectively, were
included into the multivariate model where 9, 4, and 8
independent correlates of ST, MB, and death were identi-
fied, respectively (Table 5).
Figure 2 shows the incidence of ST and MB among
patients grouped according to various clinical and angio-
graphic characteristics, and Figure 3 shows the incidence
of ST and MB over time. The cumulative incidence of
both adverse events reached 1.0% at 1 year. However,
despite the lower prevalence of DAPT, the incidence of
ST between 6 and 12 months remained considerably
lower than between 0 and 6 months, whereas the rate of
MB was nearly linear. All-cause mortality throughout the
follow-up was 35% after ST and 10% after MB. Mortality
during the first week after ST and MB was 30% and
1.5%, respectively, suggesting a more direct causal rela-
tionship between death and ST. It is also noteworthy that
85% of patients who died within 7 days after ST did so
within 30 days after the index procedure, whereas the 2
deaths occurring within 7 days after MB occurred on
Days 155 and 265 of follow-up, respectively. Compliance
with DAPT at the time of each ST is shown in Figure 4.
The risk of discontinuing or interrupting 1 or both
antiplatelet agents within 30 days after the index proce-
dure was very high, before decreasing rapidly.
Stent thrombosis was very closely associated with fatal
outcomes, MI, and target vessel revascularization but not
with MB (Table 6). Only 2 of 13,749 patients (0.015%)
experienced both MB and ST during the entire 1-year
period of observation. Both patients had undergone SES
implantation after presenting with ACS, and both haddiscontinued DAPT, for gastrointestinal bleeding on Day 5
and intracranial bleeding on Day 115, respectively. Both
patients experienced definite ST within 1 week of discon-
tinuing DAPT.
Target lesion revascularization occurred in 309 patients
(2.3%) during the 1-year follow-up. No case of ST was
reported to have occurred after TLR. Two of the 309
patients experienced MB on the day of TLR; in both cases
this was access-site related.
Discussion
The e-SELECT registry contributes the first analysis of the
incidence and relative clinical impact of ST and MB in a
very large, unselected sample of SES recipients. It reveals a
low rate of ST and MB after successful implantation of 1
ES and a good overall reported compliance with the
uidelines issued by the ESC regarding the administration
f antithrombotic therapy after PCI (9).
Characteristics of 19,988 Target Lesionsand 23,492 Stents in 15,147 PatientsTable 2 Characteristics of 19,988 Target Lesionsand 23,492 Stents in 15,147 Patients
Lesion characteristics
Reference vessel diameter, mm* 2.92 0.46
Pre-procedural percent stenosis* 84.5 12.4
Lesion length, mm* 22.2 11.6
Lesion subsets
Restenotic lesion 2,314 (11.8)
In-stent restenosis 474 (2.4)
Lesion length 30 mm 2,655 (13.3)
Bifurcation lesion 2,437 (12.4)
3-month-old total occlusion 617 (3.1)
Reference vessel diameter 2.25 mm 771 (3.9)
Ostial lesion 2,476 (12.6)
Moderately or severely calcified lesion 4,202 (23.6)
Procedural characteristics
Numbers per procedure
Vessels treated 1.2 0.4
Lesions treated 1.3 0.6
Stents implanted 1.6 0.9
Number of procedures with overlapping stents 2,218 (14.7)
Total stent length, mm
Per lesion 25.4 13.2
Per procedure 33.5 21.0
Direct stenting 7,012 (35.7)
Post-dilation 8,056 (36.1)
Maximum pressure, atm 17.1 4.3
Intravascular ultrasound imaging 713 (3.7)
Antithrombotic medication
Pre-procedural
Aspirin 12,723 (85.8)
Ticlopidine 281 (1.9)
Clopidogrel 8,957 (60.4)
Intraprocedural
Glycoprotein IIb/IIIa inhibitor 2,353 (15.7)
Bivalirudin 473 (3.2)Values are mean  SD or n (%) of observations. *Investigator reported visual estimate.
g.
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March 29, 2011:1445–54 Thrombosis and Bleeding After SES ImplantThe 1.0%, 1-year rate of definite and probable ST, as
defined by the Academic Research Consortium, is in the lower
range reported by previous registries and randomized DES
trials (1,7,20,21–23). This might partly be explained by the
selection of patients who had undergone technically suc-
Antithrombotic Regimens Up to 360 Days of Follow-UpTable 3 Antithro botic Regimens Up to 360 Days of Follow-Up
At Discharge
Antithrombotic regimen n  14,849
Dual antiplatelet therapy 14,648 (98.7)
Single antiplatelet therapy 189 (1.3)
Aspirin 12 (6.0)
Thienopyridine 177 (94.0)
No antiplatelet therapy 8 (0.05)
Causes for interruptions and discontinuations
Temporary interruptions
Physician’s order
Surgery/dental procedure
Allergy/intolerance
Bleeding
Omission/financial constraints
Switch to AVK
Undetermined
Permanent discontinuations
Physician’s order
Surgery/dental procedure
Allergy/intolerance
Bleeding
Omission/financial constraints
Switch to AVK
Undetermined
Values are n (%) of observations. Temporary interruptions and permanent discontinuations refer t
of patients, because patients might have had different reasons for each separate antiplatelet dru
AVK  antivitamin K agents.
Cumulative Rates of Adverse Clinical Events atand 1-Year Follow-UpTable 4 Cumulative Rat s of Advers Clinicand 1-Year Follow-Up
Up to 3
Adverse clinical events n  1
Death 53 (
Cardiac 44 (
Noncardiac 9 (
Myocardial infarction 157 (
Q-wave 34 (
Non–Q-wave 123 (
Target lesion revascularization 58 (
Percutaneous 58 (
Surgical 0 (
All major adverse cardiovascular events 213 (
Stent thrombosis
Definite 56 (
Probable 30 (
Possible 1 (
Major bleeding 57 (Values are n (%) of observations.cessful procedures (i.e., recipients of 1 SES implanted as
planned) and by a high compliance with DAPT. In addi-
tion, patients perceived to be at high risk of bleeding might
have been treated with bare-metal stents and not entered in
this registry. Furthermore, consistently lower rates of ST
Follow-Up
30 Days 180 Days 360 Days
n  14,365 n  13,809 n  13,533
14,076 (98.2) 13,069 (94.7) 10,744 (79.4)
231 (1.3) 659 (4.8) 2,617 (19.3)
42 (18.0) 384 (58.0) 2,236 (85.0)
189 (82.0) 275 (42.0) 381 (15.0)
29 (0.2) 75 (0.5) 164 (1.2)
n  172 n  345 n  465
62 (36) 93 (27) 126 (27)
15 (9) 88 (26) 166 (36)
8 (5) 12 (3) 1 (0.2)
18 (10) 25 (7) 19 (0.4)
44 (26) 88 (26) 84 (18)
0 (0) 2 (0.6) 1 (0.2)
27 (16) 43 (12) 76 (16)
n  116 n  583 n  2,607
29 (25) 323 (55) 2,139 (82)
3 (3) 28 (5) 57 (2.2)
22 (19) 32 (5) 46 (1.7)
10 (9) 38 (7) 76 (2.9)
15 (13) 47 (8) 111 (4)
13 (11) 29 (5) 50 (2)
27 (23) 93 (16) 163 (6)
in, thienopyridine, or both. The total number of reasons does not have to be equal to the number
ay, 6-Month,ents at 30-Day, 6-Month,
ys After Index Stent Implantation Procedure
s Up to 180 Days Up to 360 Days
n  14,572 n  13,897
132 (0.9) 236 (1.7)
82 (0.6) 136 (1.0)
50 (0.3) 100 (0.7)
217 (1.5) 264 (1.9)
47 (0.3) 57 (0.4)
170 (1.2) 208 (1.5)
155 (1.2) 309 (2.3)
157 (1.1) 280 (2.0)
12 (0.1) 37 (0.3)
418 (2.9) 671 (4.8)
79 (0.5) 88 (0.6)
44 (0.3) 47 (0.3)
20 (0.1) 56 (0.4)
99 (0.7) 131 (1.0)o aspir30-Dal Ev
Da
0 Day
4,985
0.4)
0.3)
0.1)
1.1)
0.2)
0.8)
0.4)
0.4)
0.0)
1.4)
0.4)
0.2)
0.01)
0.4)
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stents, particularly over long follow-ups. In the Bern-
Rotterdam registry, the rate of definite ST was 3.6% at 4
years with paclitaxel-eluting stents versus 2.7% with SES
(p  0.019) (7).
Previous studies of bleeding complications after PCI in
patients presenting with ACS have reported rates of MB
between 1.8% and 9.2% (10–15). In a registry of 10,974
unselected patients, Kinnaird et al. (16) reported a 5.4%
incidence of MB as defined by the Thrombolysis In Myo-
cardial Infarction criteria; two-thirds were related to the
vascular access site. With a risk score based on multiple
demographic, clinical, and procedural characteristics, Nikol-
sky et al. (24) reported a risk of MB ranging between 1.0%
and 5.4% after PCI performed via the femoral access. In
22,798 patients 65 years of age, late MB after PCI—
Figure 1 Major Bleeding Complications in 131 Patients
Major bleeding complications according to the STEEPLE (Safety and efficacy of Eno
or whole blood; or †10% decrease in hemoglobin (Hb) or hematocrit; ‡hematom
Correlates Up to 360 Days of Death, ST, and MB by Multivariate RTable 5 Correlates Up to 360 Days of Death, ST, and MB by M
Correlates Death
Index procedure ST 22.5 (15.8–32.0)
MB 6.0 (3.3–10.8)
Insulin-dependent diabetes 1.9 (1.4–2.6)
Age (in 10-yr increments) 1.6 (1.4–1.9)
Charlson comorbidity index (in 1-point increments) 1.2 (1.1–1.2)
Total number of lesions treated 1.3 (1.1–1.6)
Glycoprotein IIb/IIIa inhibitor 0.6 (0.4–0.8)
Hyperlipidemia at baseline 0.7 (0.5–0.9)
Bypass graft target lesion —
Any discontinuation of DAPT during the first 30 days —
Acute coronary syndrome at presentation —
Multi-vessel coronary disease —
Target lesion calcification —
History of myocardial infarction —
Chronic AVK treatment during the first 30 days —Values are hazard ratio (95% confidence interval).
AVK  antivitamin K (oral anticoagulants); DAPT  dual antiplatelet therapy; MB  major bleeding; Smainly from gastrointestinal sources—prompted the repeat
hospital stay of 2.5% of patients (25). In the CHARISMA
(Clopidogrel for High Atherothrombotic Risk and Ischemic
Stabilization, Management, and Avoidance) trial, at a mean
follow-up of 27 months, the incidence of MB during
DAPT was 1.7% in clinically stable patients with known
vascular disease, of whom nearly one-fourth had received a
coronary stent before enrollment in the trial (26).
In this registry, two-thirds of ST occurred within the first
30 days after the index procedure, an observation concor-
dant with earlier reports (1,7,27,28). Furthermore, the
incidence of ST decreased after the first 6 months, in
contrast with MB. These observations challenge the wis-
dom of continuing DAPT beyond 6 months after the
implantation of SES in all patients—considering the risk of
MB associated with the prolonged administration of
in in PCI) definitions in 131 patients. *Transfusion of 1 U of red blood cells
m and/or requiring prolonged hospital stay and/or protamin therapy.
sion Analysisriate Regression Analysis
alue ST p Value MB p Value
.001 NA —
.001 — NA
.001 2.1 (1.4–3.2) 0.001 —
.001 1.2 (1.0–1.4) 0.02 1.4 (1.1–1.6) 0.001
.001 1.2 (1.1–1.4) 0.001 1.1 (1.0–1.2) 0.004
.01 — —
.006 — 2.3 (1.5–3.4) 0.001
.002 — —
4.3 (2.4–7.7) 0.001 —
3.2 (1.8–5.5) 0.001 —
1.8 (1.3–2.6) 0.001 —
1.6 (1.1–2.2) 0.01 —
1.6 (1.2–2.3) 0.005 —
1.4 (1.0–2.0) 0.03 —
— 3.7 (1.6–8.4) 0.002xapar
a 5 cegresultiva
p V
0
0
0
0
0
0
0
0T  stent thrombosis.
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against ST—a point first made by Airoldi et al. (29). The
issue should be resolved by ongoing randomized trials, such
as the ISAR-SAFE (Intracoronary Stenting and Anti-
thrombotic Regimen: Safety And EFficacy of Six Months
Dual Antiplatelet Therapy After Drug-Eluting Stenting)
Figure 2 Stent Thrombosis and Major Bleeding in Selected Pat
Stent thrombosis (Academic Research Consortium definite and probable) and majo
of observations in selected subgroup (the number of observations for each subgro
patients; insulin-nondependent diabetes mellitus (NIDDM): 3,011 patients; serum
globin (Hb) 117 g/l: 724 patients; anticoagulated with antivitamin K (AVK) agent
multivessel disease (MVD): 2,052 patients; prior coronary artery bypass graft surg
(GP) IIb/IIIa inhibitors: 2,120 patients.
Figure 3 Incidence of Definite or Probable
Stent Thrombosis and Major Bleeding
Cumulative incidence of stent thrombosis (Academic Research Consortium defi-
nite and probable) and major bleeding (STEEPLE definition) in the overall
population.study, in which 6,000 patients are being randomly assigned
to 6 versus 12 months of DAPT (30), and the DAPT (Dual
Antiplatelet Therapy) study of 20,645 patients randomly
assigned to 12 versus 30 months of antithrombotic therapy.
Recently published data from Park et al. (31) suggest no
additional benefit from prolonged DAPT beyond 12
months in patients who have remained free from adverse
clinical event during the first year after DES implantation.
Stent thrombosis was the cause of considerably higher
mortality and cardiovascular morbidity than MB. Further-
more, the risk of dying was very high in the first 7 days after
ST, whereas it was more evenly distributed throughout the
follow-up after MB. Thus, bleeding might often be a
Subgroups
ding (STEEPLE definition) in selected patient subgroups. Values are percentages
s: all patients: 13,749; insulin-dependent diabetes mellitus (IDDM): 1,096
nine (creat.) 177 mol/l: 241 patients; age 80 years: 601 patients; hemo-
seline: 266 patients; acute myocardial infarction (AMI) 24 h: 1,131 patients;
ABG): 1,242 patients; Charlson index 3: 1,383 patients; use of glycoprotein
Relationships Among ARC Definite or Probable ST andCardiac Death, Myocardial Infarc ion, TVR, and MB at1-Year Follow-Up
Table 6
Relati nships Amo g ARC Definite or Probable ST and
Cardiac Death, Myocardial Infarction, TVR, and MB at
1-Year Follow-Up
ST
(n  135)
No ST
(n  13,614)
All Patients
(n  13,749)
Cardiac death 46 (34) 90 (0.7) 136 (1.0)
Myocardial infarction 91 (67) 173 (1.3) 264 (1.9)
TVR 91 (67) 356 (0.3) 447 (3.3)
MB 2 (1.5) 129 (1.0) 131 (1.0)
Values are n (%) of observations in corresponding group.ient
r blee
up wa
creati
at ba
ery (CARC  Academic Research Consortium; TVR  target vessel revascularization; other abbrevia-
tions as in Table 5.
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outcome.
Our data contributed another important observation: de-
spite sharing several risk factors for ST and MB, individual
patients who experienced adverse events were either “bleeders”
or “clotters”—not both. Other large trials have shown that the
higher mortality associated with bleeding complications is not
necessarily due to an increase in coronary artery disease-related
adverse events (10,32). This might limit the clinical contribu-
tion of bleeding scores (14,15,33,34) in the adjustment of
long-term antithrombotic treatment after stent implantation,
because they often define a population at increased risk of both
bleeding and ST. In this registry, advanced age and a high
Charlson comorbidity index score (18) were independent
predictors of both ST and MB. Therefore, the reliable iden-
tification of individual hemostatic profiles and responses to
antithrombotic therapy would seem highly desirable, whether
by genotyping (35,36) or by a fully validated platelet function
test (37). The administration of new antiplatelet agents might
also be associated with a different ST/MB ratio (4,5). In this
analysis, the risk of ST was increased in insulin-dependent
diabetic subjects, whereas the risk of MB was nearly the same
as in nondiabetic subjects, suggesting that—in this group of
patients—a more potent antiplatelet agent, such as prasugrel,
might be particularly beneficial, as observed for ACS patients
in the TRITON–TIMI 38 (Trial to assess Improvement in
Therapeutic Outcomes by optimizing platelet Inhibition with
prasugrel–Thrombolysis In Myocardial Infarction 38) (5).
tudy limitations. Although enrolling all consecutive pa-
ients treated with SES was strongly encouraged in all
articipating centers, no information was collected on pa-
ients treated with SES but not enrolled in the e-SELECT
egistry; also, the use of stents other than SES during the
Figure 4 Compliance With Antithrombotic Regimens at the Tim
Compliance with antithrombotic regimens at the time of stent thrombosis (Academndex procedure was an exclusion criterion. Both these Wactors might have contributed to some degree of selection
ias. We monitored the source data collected in a random
ample representing 20% of the patients enrolled in the
-SELECT registry: Although this compares favorably with
ther recent stent registries (27,28,38), the under-reporting
f adverse events remains a potential limitation. Neverthe-
ess, we observed consistent and accurate data collections in
he monitored sample, and the 1.5% rate of definite ST at 1
ear among our patients enrolled with ST-segment eleva-
ion MI was close to the 2.0% reported in the fully
onitored randomized TYPHOON (Trial to Assess the
se of the Cypher Stent in Acute Myocardial Infarction
reated with Balloon Angioplasty) of the same SES (20).
ikewise, the 0.6% rate of definite ST among all patients
nrolled in the e-SELECT registry is very close to the 0.4%
bserved in the combined analysis of 4 pivotal randomized
rials (1). The follow-up period was only 1 year: it is possible
hat the relative risks of ST and MB are different over a
onger period, especially because compliance with DAPT
ould be expected to drop significantly beyond the 1-year
ark. The baseline and procedural characteristics of the 8%
f patients lost to follow-up at 1 year were not markedly
ifferent from those followed up to 1 year. Finally, we did
ot collect data regarding the vascular access site, and
herefore the impact of radial versus femoral catheterization
n the rate of MB could not be ascertained (39).
onclusions
he 1-year incidence of ST and MB in this large sample of
nselected patients successfully treated with 1 SES was
ow, and patients showed good compliance with the ESC
uidelines for antiplatelet therapy during the first year.
Stent Thrombosis
earch Consortium definite or probable).e of
ic Reshile advanced age and a high Charlson index increased
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March 29, 2011:1445–54 Thrombosis and Bleeding After SES Implantthe risk of both ST and MB, and ST and MB often
occurred in the same patient subsets, individual patients
who experienced adverse events were either “bleeders” or
“clotters” and very rarely experienced both adverse events
during the first year of follow-up. These observations
suggest that the safety of SES could be enhanced by the
precise identification of the hemostatic profile and response
to antithrombotic therapy of an individual patient as well as
by new DES designs, which would allow shorter and less
intense antithrombotic regimens.
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